January’s investment activity saw a wave of biotech Series funding, with Verdiva Bio, Aviceda Therapeutics, Windward Bio, and …
January’s investment activity saw a wave of biotech Series funding, with Verdiva Bio, Aviceda Therapeutics, Windward Bio, and …
Atalanta Therapeutics raises $97 million in Series B funding to accelerate RNA interference therapies into Phase 1 trials, …
Despite a cautious capital environment, North American biotech companies secured nearly $2 billion in funding in January 2025, with …
As traditional VC investment remains selective, firms like Abingworth and Vie Ventures are pioneering fresh approaches—launching billion-dollar trials …
Shanghai-based Excalipoint secures rights to two preclinical T-cell engagers from Lepu Biopharma, aiming to fast-track development for solid …
Blending single-cell biology with generative AI, Cellarity launches its first-in-human trial for CLTY-101—an engineered cell therapy targeting tumor …
With a blockbuster IPO on the horizon, Australian biotech innovation is drawing global eyes and fresh capital to …
New partnerships and funding rounds are powering the rapid growth of RNA therapeutics.
New device approval and robust oncology funding highlight ongoing biopharma momentum in cancer therapies.
While VC investment cools, innovative startups find new ways to fuel biotech innovation and clinical progress.
Already a subscriber? Log in